Peter Maccallum Cancer Centre, Australia

This study looks at whether adding a precise, high-dose radiation treatment called SABR to ongoing hormone therapy and CDK 4/6 inhibitors can delay the need to switch to a new cancer treatment in people with ER-positive, HER2-negative advanced breast cancer. About 74 participants…

This study tests a new radioactive drug, Lu-177 FAP-2286, in 20 adults with cancer of unknown primary (CUP) that has worsened after standard chemotherapy. The goal is to see if the drug can shrink tumors or stop the cancer from growing. Participants receive the drug intravenously…

This early-phase study tests a new treatment for people with a type of multiple myeloma that has returned or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals ar…

This study tracks 75 women with early-stage triple-negative breast cancer to see how chemotherapy combined with immunotherapy affects their ovaries and fertility. Participants will give blood samples and answer questionnaires before and after standard treatment, with follow-up fo…